Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Joe Kiani Co-Founder Masimo Corp. The latest legal battle between Irvine-based medical device maker Masimo Corp. and Apple ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for the third quarter, representing a 12% growth compared ...

the Masimo W1 Medical watch. “If you really want a wearable that’s going to help you manage your health, the accuracy of that signal has got to be at the highest caliber,” says Omar Ahmed ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

In this article, we are going to take a look at where Masimo Corporation (NASDAQ ... Overall, even while funding for digital health had been rising gradually in the years preceding the pandemic ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...